

Addendum

Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLEET study

Silvia P. Corona¹, Fabiola Giudici^{1,2}, Guy Jerusalem³, Eva Ciruelos⁴, Carla Strina⁵, Marianna Sirico⁶, Ottavia Bernocchi¹, Manuela Milani⁵, Martina Dester⁵, Nicoletta Ziglioli⁵, Giuseppina Barbieri⁵, Valeria Cervoni⁵, Filippo Montemurro⁷ and Daniele Generali^{1,5}

¹Department of Medicine, Surgery and Health Sciences, University of Trieste, Cattinara Hospital, Trieste, Italy

²Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy

³CHU Sart Tilman Liège and Liège University, Liège, Belgium

⁴Hospital Universitario 12 de Octubre, Madrid, Spain

⁵Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, Cremona, Italy

⁶Università Cattolica del Sacro Cuore, Roma, Italy

⁷Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy

Published: December 06, 2022

Copyright: © 2022 Corona et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Written informed consent was obtained from all patients. The study protocol was approved by an independent ethics committee or institutional review board at each site.

Original article: Oncotarget. 2020; 11:2172–2181. <https://doi.org/10.18632/oncotarget.27612>